Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

22.72

+0.89 (4.08%)

At close: Feb 20, 2026, 4:00 PM EST

22.28

-0.44 (-1.94%)

After-hours: Feb 20, 2026, 7:20 PM EST

Ultragenyx Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	173.73	213.58	132.94	307.58
Short-Term Investments	-	436.3	363.63	614.82	432.61
Cash & Short-Term Investments	425.25	610.03	577.21	747.76	740.2
Cash Growth	-30.29%	5.68%	-22.81%	1.02%	-38.40%
Accounts Receivable	-	121.8	73.39	40.45	28.43
Other Receivables	-	1.8	1.1	6.4	16
Receivables	-	123.6	74.49	46.85	44.43
Inventory	-	45.01	33.97	26.77	16.23
Prepaid Expenses	-	31.68	44.51	-	55.75
Restricted Cash	-	6.81	2.01	0.86	-
Other Current Assets	-	-	-	61.66	-
Total Current Assets	-	817.12	732.18	883.9	856.6
Property, Plant & Equipment	-	291.43	314.47	285.73	176.18
Long-Term Investments	-	135	199.9	148.97	293.86
Goodwill	-	44.41	44.41	44.41	44.41
Other Intangible Assets	-	178.31	166.27	160.11	130.79
Other Long-Term Assets	-	37.18	33.79	22.34	20.56
Total Assets	-	1,503	1,491	1,545	1,522
Accounts Payable	-	38.76	42.11	43.27	17.14
Accrued Expenses	-	240.97	196.49	204.68	145.56
Current Portion of Long-Term Debt	-	49.85	29.24	-	-
Current Portion of Leases	-	10.3	12.6	11.78	11.07
Current Unearned Revenue	-	-	-	1.48	7.61
Other Current Liabilities	-	4.28	-	-	-
Total Current Liabilities	-	344.15	280.44	261.21	181.37
Long-Term Debt	-	819.82	862.33	875.44	351.79
Long-Term Leases	-	30.04	30.57	19.81	30.9
Long-Term Unearned Revenue	-	-	-	-	1.47
Long-Term Deferred Tax Liabilities	-	30.06	30.06	31.67	33.31
Other Long-Term Liabilities	-	17.08	12.21	4.82	1.01
Total Liabilities	-	1,241	1,216	1,193	599.84
Common Stock	-	0.09	0.08	0.07	0.07
Additional Paid-In Capital	-	4,213	3,662	3,140	2,997
Retained Earnings	-	-3,957	-3,388	-2,781	-2,074
Treasury Stock	-	-3.59	-0.43	-	-
Comprehensive Income & Other	-	2.95	1.08	-6.57	-1.4
Total Common Equity	9.16	255.3	275.41	352.49	922.56
Minority Interest	-	7	-	-	-
Shareholders' Equity	16.16	262.3	275.41	352.49	922.56
Total Liabilities & Equity	-	1,503	1,491	1,545	1,522
Total Debt	863.11	910.01	934.74	907.03	393.76
Net Cash (Debt)	-415.8	-164.98	-157.63	-10.3	605.37
Net Cash Growth	-	-	-	-	-26.90%
Net Cash Per Share	-4.22	-1.82	-2.14	-0.15	8.93
Filing Date Shares Outstanding	96.3	92.5	82.34	70.22	69.38
Total Common Shares Outstanding	96.27	92.48	82.32	70.2	69.34
Working Capital	-	472.97	451.75	622.69	675.24
Book Value Per Share	0.10	2.76	3.35	5.02	13.30
Tangible Book Value	-208.19	32.58	64.74	147.98	747.37
Tangible Book Value Per Share	-2.16	0.35	0.79	2.11	10.78
Land	-	16.62	16.62	16.62	15.49
Buildings	-	181.58	181.36	2.8	-
Machinery	-	120.41	116.26	70.28	54.31
Construction In Progress	-	-	-	189.45	76.85
Leasehold Improvements	-	58.02	58.68	43.94	44.08

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q